ESTRO meets Asia 2024 - Abstract Book

S60

Interdisciplinary – Brachytherapy

ESTRO meets Asia 2024

diagnosis increases risk with a 1.006 and 1.012 times higher chance of developing of biochemical recurrence and cancer-specific mortality. Gleason score > 7 significantly increases risk of cancer-specific mortality with a HR of 2.994. and biochemical recurrence with a HR of 2.424. Tumor stage T3b increases risk with a 4.776 times higher chance of developing biochemical recurrence.

Conclusion:

HDR-BT boost plus EBRT combination schema provides excellent long-term survival probabilities. PSA at diagnosis, Gleason > 7 and tumor stage T3b are adverse prognosis factors of 20-year BFS and CSFS. No significant difference was found in 10-year BFS, MFS, CSFS and GITFS for patients receiving single-fraction or 2 fraction regimes during HDR-BT boost administration, whereas weak evidence was found regarding GUTFS.

Keywords: prostate, HDR, boost

290

Digital Poster

Patient-specific Intravascular Brachytherapy Dosimetry and the Guidewire Cold-Spot Effect

Maryam Rahbaran 1,2 , Brian A Bergmark 3 , Kevin J. Croce 3 , James M.G. Tsui 4 , Phillip M. Devlin 5 , Shirin A. Enger 1,2

1 Department of Oncology, McGill University, Montréal, Canada. 2 Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Canada. 3 Department of Cardiology, Brigham and Women's Hospital, Boston, USA.